Relationship between treatment for hematological malignancies and testicular toxicity (19)
| Intervention . | Indications . |
|---|---|
| High risk: prolonged azoospermia after treatment | |
| TBI | HSCT |
| Testicular radiation dose >2.5 Gy in men, >6 Gy in boys | Testicular lymphoma |
| Protocols containing procarbazine (MOPP, COPP) | HL |
| Alkylating chemotherapy for transplantation conditioning (cyclophosphamide, busulfan, melphalan) | HSCT |
| Cyclophosphamide >7.5 g/m2 | NHL |
| Cranial/brain radiation >40 Gy | CNS involvement |
| Intermediate risk: prolonged azoospermia not common at standard dose | |
| Cumulative cisplatin dose >400 mg/m2 | Salvage regimen for lymphoma |
| Cumulative carboplatin dose >2 g/m2 | Salvage regimen for lymphoma |
| Low risk: temporary azoopenia after treatment | |
| ABVD | HL |
| CHOP | NHL |
| Anthracycline + cytarabine | AML |
| Multiagent therapies for leukemia | ALL |
| Non-alkylating chemotherapy | |
| Unknown risk | |
| Tyrosine kinase inhibitors | CML, ALL with t(9;22)(q34.1;q11.2) |
| Intervention . | Indications . |
|---|---|
| High risk: prolonged azoospermia after treatment | |
| TBI | HSCT |
| Testicular radiation dose >2.5 Gy in men, >6 Gy in boys | Testicular lymphoma |
| Protocols containing procarbazine (MOPP, COPP) | HL |
| Alkylating chemotherapy for transplantation conditioning (cyclophosphamide, busulfan, melphalan) | HSCT |
| Cyclophosphamide >7.5 g/m2 | NHL |
| Cranial/brain radiation >40 Gy | CNS involvement |
| Intermediate risk: prolonged azoospermia not common at standard dose | |
| Cumulative cisplatin dose >400 mg/m2 | Salvage regimen for lymphoma |
| Cumulative carboplatin dose >2 g/m2 | Salvage regimen for lymphoma |
| Low risk: temporary azoopenia after treatment | |
| ABVD | HL |
| CHOP | NHL |
| Anthracycline + cytarabine | AML |
| Multiagent therapies for leukemia | ALL |
| Non-alkylating chemotherapy | |
| Unknown risk | |
| Tyrosine kinase inhibitors | CML, ALL with t(9;22)(q34.1;q11.2) |
TBI, total body irradiation; HSCT, hematopoietic stem cell transplantation; MOPP, mechlorethamine, vincristine, procarbazine and prednisone; COPP, cyclophosphamide, vincristine, procarbazine and prednisone; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; CNS, central nervous system; ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia.
Relationship between treatment for hematological malignancies and testicular toxicity (19)
| Intervention . | Indications . |
|---|---|
| High risk: prolonged azoospermia after treatment | |
| TBI | HSCT |
| Testicular radiation dose >2.5 Gy in men, >6 Gy in boys | Testicular lymphoma |
| Protocols containing procarbazine (MOPP, COPP) | HL |
| Alkylating chemotherapy for transplantation conditioning (cyclophosphamide, busulfan, melphalan) | HSCT |
| Cyclophosphamide >7.5 g/m2 | NHL |
| Cranial/brain radiation >40 Gy | CNS involvement |
| Intermediate risk: prolonged azoospermia not common at standard dose | |
| Cumulative cisplatin dose >400 mg/m2 | Salvage regimen for lymphoma |
| Cumulative carboplatin dose >2 g/m2 | Salvage regimen for lymphoma |
| Low risk: temporary azoopenia after treatment | |
| ABVD | HL |
| CHOP | NHL |
| Anthracycline + cytarabine | AML |
| Multiagent therapies for leukemia | ALL |
| Non-alkylating chemotherapy | |
| Unknown risk | |
| Tyrosine kinase inhibitors | CML, ALL with t(9;22)(q34.1;q11.2) |
| Intervention . | Indications . |
|---|---|
| High risk: prolonged azoospermia after treatment | |
| TBI | HSCT |
| Testicular radiation dose >2.5 Gy in men, >6 Gy in boys | Testicular lymphoma |
| Protocols containing procarbazine (MOPP, COPP) | HL |
| Alkylating chemotherapy for transplantation conditioning (cyclophosphamide, busulfan, melphalan) | HSCT |
| Cyclophosphamide >7.5 g/m2 | NHL |
| Cranial/brain radiation >40 Gy | CNS involvement |
| Intermediate risk: prolonged azoospermia not common at standard dose | |
| Cumulative cisplatin dose >400 mg/m2 | Salvage regimen for lymphoma |
| Cumulative carboplatin dose >2 g/m2 | Salvage regimen for lymphoma |
| Low risk: temporary azoopenia after treatment | |
| ABVD | HL |
| CHOP | NHL |
| Anthracycline + cytarabine | AML |
| Multiagent therapies for leukemia | ALL |
| Non-alkylating chemotherapy | |
| Unknown risk | |
| Tyrosine kinase inhibitors | CML, ALL with t(9;22)(q34.1;q11.2) |
TBI, total body irradiation; HSCT, hematopoietic stem cell transplantation; MOPP, mechlorethamine, vincristine, procarbazine and prednisone; COPP, cyclophosphamide, vincristine, procarbazine and prednisone; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; CNS, central nervous system; ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
